Drug Profile
TT 16
Alternative Names: HER2-CAR VSTs + Oncolytic & Helper Adenovirus; HER2-CAR VSTs + Oncolytic & Helper Adenovirus - Tessa Therapeutics; HER2-specificCAR- T; TT16Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Tessa Therapeutics
- Developer Baylor College of Medicine; Tessa Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; Oncolytic viruses; Viruses
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Head and neck cancer; Solid tumours
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA (Intratumoural, Injection)
- 28 Jun 2023 No recent reports of development identified for preclinical development in Solid-tumours in Singapore (Parenteral)
- 06 Dec 2022 Efficacy and adverse events data from phase I trial in Solid tumours presented at the 45th Annual San Antonio Breast Cancer Symposium (SABCS-2022)